Lacking Revenue, Jenscare Scientific Hopes IPO Investors Take Heart in Its Potential
The maker of devices to treat structural heart disease hopes to have its first product approved in the second half of next year as it prepares to list in Hong…
RELATED ARTICLES
-
Venus Medtech still seeking cure for governance problems
2500.HK
-
Rebounding Perfect Medical finds beauty safe haven in Hong Kong
1830.HK
- Medical imaging group Rimag sets growth focus with IPO
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
FAST NEWS: Venus Medtech’s loss narrows on surging overseas sales
2500.HK
-
MedBot seeks commercial edge with dual-use surgical robot
2252.HK
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
Discover hidden China stock gems in our weekly newsletter